Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Browse creative work from home business ideas that can help you start earning. Discover the perfect fit for your skills!
18,910 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
CubeSmart sits in a crowded self-storage field. This guide breaks down the key indicators I watch to assess whether C...
A rally in AeroVironment shares has investors wondering what sparked the move. This guide breaks down the factors beh...
As markets navigate early-2026 volatility, three dividend-focused ETFs stand out for beginners. Low fees, broad diver...
Analysts say the doom loop helps explain why the global economy is growing bleaker in 2026. High borrowing costs, wea...
A director sold about $128,000 of Cognex shares, prompting questions about the stock's outlook. This guide breaks dow...
IBM's shares sank as Anthropic's Claude Code intensifies AI competition, pushing ibm’s stock heads worst for a month ...
Hims & Hers beat quarterly EPS but trimmed full-year guidance, extending a slide in its stock as regulatory headwinds...
Axon is set to report Q4 2025 results after the close, as Wall Street weighs software momentum, AI-era bookings, and ...
In a long, closely watched State of the Union address, President Trump steered clear of tariff refunds and trade reme...
IonQ posted quarterly results that beat expectations, triggering a notable after-hours rally. Analysts warn the stock...
Urban Outfitters posted a strong Q4 2026 with record revenue, led by a rebound in its flagship Urban Outfitters brand...